27.72% of Alaunos Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Alaunos Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/20/2024	Virtu Financial LLC	15,440	$28K	0.0%	N/A	0.096%
5/2/2024	Magnolia Capital Advisors LLC	24,695	$45K	0.0%	-93.8%	0.154%
4/30/2024	Fortis Group Advisors LLC	13,999	$25K	0.0%	N/A	0.087%
2/20/2024	MSD Partners L.P.	15,151,516	$1.07M	0.1%	-33.3%	94.402%
2/9/2024	Commerce Bank	437,000	$31K	0.0%	-4.8%	2.723%
2/2/2024	Magnolia Capital Advisors LLC	401,507	$28K	0.0%	-7.3%	0.167%
11/4/2023	Magnolia Capital Advisors LLC	432,969	$56K	0.1%	N/A	0.180%
7/20/2023	Allred Capital Management LLC	253,000	$0.13M	0.1%	+24.6%	0.105%
5/12/2023	CIBC Private Wealth Group LLC	50,400	$32K	0.0%	+65.8%	0.021%
4/21/2023	Chiron Capital Management LLC	81,830	$52K	0.0%	-22.7%	0.034%
2/15/2023	Allred Capital Management LLC	193,000	$0.13M	0.1%	+22.2%	0.089%
2/14/2023	Discovery Capital Management LLC CT	16,185,998	$10.51M	1.5%	+10.5%	7.487%
2/13/2023	GSA Capital Partners LLP	957,348	$0.62M	0.1%	+57.4%	0.443%
1/30/2023	Welch Group LLC	43,000	$28K	0.0%	-26.7%	0.020%
1/9/2023	Addison Capital Co	15,870	$2.32M	1.5%	N/A	0.007%
11/15/2022	Laurion Capital Management LP	4,220,500	$7.26M	0.0%	-1.6%	1.952%
11/15/2022	Magnolia Capital Advisors LLC	418,569	$0.72M	0.6%	+25.1%	0.194%
11/15/2022	Boxer Capital LLC	1,500,000	$2.58M	0.1%	N/A	0.694%
11/15/2022	Caxton Associates LP	311,974	$0.54M	0.1%	+209.8%	0.144%
11/14/2022	Zacks Investment Management	44,550	$77K	0.0%	N/A	0.021%
11/14/2022	Tudor Investment Corp Et Al	39,374	$68K	0.0%	-88.1%	0.018%
11/14/2022	Cubist Systematic Strategies LLC	349,867	$0.60M	0.0%	+4,589.3%	0.162%
11/14/2022	Ergoteles LLC	485,434	$0.84M	0.0%	-48.2%	0.225%
11/14/2022	E Fund Management Co. Ltd.	15,167	$26K	0.0%	N/A	0.007%
11/7/2022	Virtu Financial LLC	74,592	$0.13M	0.0%	N/A	0.035%
11/3/2022	Mutual Advisors LLC	22,095	$38K	0.0%	-40.4%	0.010%
11/3/2022	Barclays PLC	136,136	$0.23M	0.0%	N/A	0.063%
10/31/2022	Concorde Asset Management LLC	35,500	$61K	0.1%	N/A	0.016%
10/31/2022	Green Square Capital Advisors LLC	1,080,000	$1.86M	0.3%	N/A	0.500%
10/26/2022	Belvedere Trading LLC	66,493	$78K	0.0%	N/A	0.031%
10/24/2022	ACT Wealth Management LLC	38,476	$66K	0.0%	N/A	0.018%
10/17/2022	SevenBridge Financial Group LLC	20,000	$34K	0.0%	N/A	0.009%
10/14/2022	Private Advisor Group LLC	119,374	$0.21M	0.0%	N/A	0.055%
10/13/2022	Chiron Capital Management LLC	116,860	$0.20M	0.1%	N/A	0.054%
10/13/2022	Welch Group LLC	58,700	$0.10M	0.0%	N/A	0.027%
10/11/2022	Sugarloaf Wealth Management LLC	79,050	$0.14M	0.0%	N/A	0.037%
10/4/2022	AdvisorNet Financial Inc	42,329	$73K	0.0%	N/A	0.020%
8/16/2022	Discovery Capital Management LLC CT	14,125,079	$17.52M	2.3%	N/A	6.541%
8/15/2022	Laurion Capital Management LP	4,289,193	$5.32M	0.1%	N/A	1.986%
8/15/2022	Kettle Hill Capital Management LLC	344,400	$0.43M	0.1%	N/A	0.159%
8/12/2022	Commerce Bank	459,000	$0.57M	0.0%	N/A	0.213%
8/10/2022	Synovus Financial Corp	33,000	$41K	0.0%	N/A	0.015%
8/8/2022	Nicolet Advisory Services LLC	21,500	$30K	0.0%	N/A	0.010%
8/8/2022	Oppenheimer & Co. Inc.	45,500	$56K	0.0%	N/A	0.021%
8/8/2022	Y Intercept Hong Kong Ltd	25,079	$31K	0.0%	N/A	0.012%
8/5/2022	Gamble Jones Investment Counsel	61,000	$76K	0.0%	N/A	0.028%
8/5/2022	Horizon Kinetics Asset Management LLC	34,000	$42K	0.0%	N/A	0.016%
8/4/2022	Steward Partners Investment Advisory LLC	36,106	$45K	0.0%	N/A	0.017%
8/3/2022	CIBC Private Wealth Group LLC	41,490	$51K	0.0%	N/A	0.019%
8/3/2022	Stephens Inc. AR	25,162	$31K	0.0%	N/A	0.012%
8/3/2022	Janney Montgomery Scott LLC	82,412	$0.10M	0.0%	N/A	0.038%

Data available starting January 2016

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

Today's Range

Now: $2.40

$2.35

$2.50

50 Day Range

MA: $3.56

$2.18

$6.78

52 Week Range

Now: $2.40

$2.11

$32.85

Volume

8,737 shs

Average Volume

15,255 shs

Market Capitalization

$38.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Alaunos Therapeutics?: Alaunos Therapeutics' top insider investors include:
Robert W Postma (Director)
Kevin S Sr Boyle (CEO)
Learn More about top insider investors at Alaunos Therapeutics.